DeutschNewstral
Article
Bbarrons.com on 2022-01-10 10:45
Molecular Partners Stock Surges as Novartis Plans to License Covid-19 Drug1 min read
Related news
- BMolecular Partners Stock Surges as Novartis Plans to License Covid-19 Drug1 min readbarrons.com
Novartis setzt auf Covid-Arzneikandidat von Molecular PartnersReuters- MConatus shares skyrocket after Novartis license dealmarketwatch.com
- MNovartis hemoglobinuria trial meets two primary endpoints1 min readmarketwatch.com
- LGlobal Levocabastine Market 2021 Financial Insights, Business Growth Strategies, Trends | Market Players: Physicians Total Care,Inc., Albany Molecular Research Inc., Novartis, Janssen Pharmaceutica…liverpoolstudentmedia.com
- DUC Berkeley partners with major pharmaceutical company Novartis to target ‘undruggable diseases’dailycal.org
- DUC Berkeley partners with major pharmaceutical company Novartis to develop curesdailycal.org
- MNovartis sales and profit drop, but backs 2022 guidance1 min readmarketwatch.com
- BThis Is What Wall Street Has Wrong About Novartis, Says CEO4 min readbarrons.com
- BBank of America, Morgan Stanley, Lockheed, Masimo, Novartis, and More Stock Market Movers2 min readbarrons.com
- BNovartis Looks Appealing, Based on Strong Drug Pipeline and Planned Sandoz Spinoff4 min readbarrons.com
- BNovartis Earnings Rise, Says Review of Sandoz Unit Progressing2 min readbarrons.com
- BFirst Citizens, Novartis, Carnival, and More Stock Market Movers1 min readbarrons.com
- BNovartis to Spend Bulk of Roche Windfall on Buying Back Stock, Not M&A3 min readbarrons.com
- BNovartis CEO Vasant Narasimhan Sees Consistent Growth While Sitting on Cash4 min readbarrons.com
- BNovartis Will Cut Up to 8,000 Jobs Under CEO's Shake-Up Plan1 min readbarrons.com
Driver’s license demand surgesMerced Sun-Star- MFirst Citizens shares leap on SVB deal as Novartis stock boosted by breast-cancer drug trial1 min readmarketwatch.com
- BNovartis CEO Continues His Shake-Up, Says It Will Save More Than $1 Billion Annually3 min readbarrons.com
- MXoma enters exclusive license agreement with Novartismarketwatch.com